Today before the opening bell, Boston Therapeutics announced that it had signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market SugarDown® in the United States on a non-exclusive basis. The marketing of SugarDown will … Continue reading →

Approximately 25.8 million Americans have diabetes, according to the National Diabetes Education Program, making the disease the seventh leading cause of death in the United States. To put it in monetary perspective, diabetes runs up an annual tab of $174 … Continue reading →

Boston Therapeutics is a pharmaceutical company focused on the development, manufacturing, and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes. PAZ320 is an integral part of the company’s initial product pipeline, which … Continue reading →

Boston Therapeutics is developing a pipeline of novel compounds to address unmet medical needs in diabetes. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes; and IPOXYNT for a wide … Continue reading →

It’s turning out to be one of the biggest epidemic waves in American history, with estimated costs nationally jumping approximately 40% in just the past 5 years, to roughly $1/4 trillion annually. The epidemic is diabetes, and the size and … Continue reading →

Boston Therapeutics is a pharmaceutical company using complex carbohydrate chemistry to advance its PAZ320 and IPOXYN drug candidates for the treatment of Type 2 diabetes. With 2013 under wraps, BTHE looks to have an exciting first half of the upcoming … Continue reading →

In the United States alone, an estimated 26 million people have Type 2 diabetes while another 80 million or so people are pre-diabetic. Recognizing that there are urgent, unfulfilled medical needs for both the pre-diabetic and diabetic community, Boston Therapeutics … Continue reading →

Boston Therapeutics is developing a pipeline of therapeutic molecules based on complex carbohydrate chemistry. This pipeline currently carries three compounds that are being fine-tuned and tested in hopes that each will become a commercialized therapeutic treatment for diabetes. Drug candidate … Continue reading →

In a Seeking Alpha article published on Tuesday, November 26, 2013, Boston Therapeutics was highlighted as a biopharmaceutical company with promising investor potential. The article pointed to factors such as the company’s potentially “blockbuster” treatment for diabetes and its experienced … Continue reading →

Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 … Continue reading →